RU2018104266A3 - - Google Patents

Download PDF

Info

Publication number
RU2018104266A3
RU2018104266A3 RU2018104266A RU2018104266A RU2018104266A3 RU 2018104266 A3 RU2018104266 A3 RU 2018104266A3 RU 2018104266 A RU2018104266 A RU 2018104266A RU 2018104266 A RU2018104266 A RU 2018104266A RU 2018104266 A3 RU2018104266 A3 RU 2018104266A3
Authority
RU
Russia
Application number
RU2018104266A
Other languages
Russian (ru)
Other versions
RU2722449C2 (ru
RU2018104266A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510489560.2A external-priority patent/CN106466484B/zh
Priority claimed from CN201510489556.6A external-priority patent/CN106466485B/zh
Application filed filed Critical
Publication of RU2018104266A3 publication Critical patent/RU2018104266A3/ru
Publication of RU2018104266A publication Critical patent/RU2018104266A/ru
Application granted granted Critical
Publication of RU2722449C2 publication Critical patent/RU2722449C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018104266A 2015-08-11 2016-08-11 Полилигандные лекарственные конъюгаты и их применения RU2722449C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510489560.2 2015-08-11
CN201510489556.6 2015-08-11
CN201510489560.2A CN106466484B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的多靶向配体-药物偶联体
CN201510489556.6A CN106466485B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的靶向配体-药物偶联体
PCT/CN2016/094704 WO2017025057A1 (en) 2015-08-11 2016-08-11 Multi-ligand drug conjugates and uses thereof

Publications (3)

Publication Number Publication Date
RU2018104266A3 true RU2018104266A3 (enExample) 2019-09-12
RU2018104266A RU2018104266A (ru) 2019-09-12
RU2722449C2 RU2722449C2 (ru) 2020-06-01

Family

ID=57983917

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018104266A RU2722449C2 (ru) 2015-08-11 2016-08-11 Полилигандные лекарственные конъюгаты и их применения

Country Status (13)

Country Link
US (2) US11571480B2 (enExample)
EP (1) EP3334500B1 (enExample)
JP (3) JP6772199B2 (enExample)
KR (2) KR102301596B1 (enExample)
CN (3) CN108135881B (enExample)
AU (2) AU2016305703B2 (enExample)
CA (1) CA2987322C (enExample)
DK (1) DK3334500T3 (enExample)
ES (1) ES2877409T3 (enExample)
MX (1) MX381031B (enExample)
RU (1) RU2722449C2 (enExample)
WO (1) WO2017025057A1 (enExample)
ZA (1) ZA201707464B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1012675A2 (pt) 2009-06-26 2016-04-05 Soricimed Biopharma Inc compostos e métodos para a detecção de cânceres expressando trpv-6 e liberação de fármacos
CN108135881B (zh) * 2015-08-11 2020-11-13 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
EP3716991A4 (en) * 2017-12-01 2021-09-08 Soricimed Biopharma Inc. TRPV6 INHIBITORS AND POLYTHERAPIES FOR THE TREATMENT OF CANCERS
US11576981B2 (en) 2017-12-06 2023-02-14 Ontario Institute For Cancer Research (Oicr) Acyl hydrazone linkers, methods and uses thereof
EP3728273A4 (en) 2017-12-22 2021-12-29 Ontario Institute for Cancer Research (OICR) Heterocyclic acyl hydrazone linkers, methods and uses thereof
WO2019134018A1 (en) * 2018-01-05 2019-07-11 Telethon Kids Institute Vaccine conjugates and uses thereof
KR20210119413A (ko) * 2019-01-30 2021-10-05 코히런트 바이오파마 (쑤저우), 리미티드 이중-리간드 약물 접합체 및 그의 용도
JP2022542560A (ja) * 2019-07-22 2022-10-05 パーデュー・リサーチ・ファウンデーション 線維芽細胞を標的とする多価作用物質、および使用方法
US20230242979A1 (en) * 2019-08-20 2023-08-03 Egi Tech (Shen Zhen) Co., Limited Method for sequencing polynucleotides based on optical signal kinetics of luminescent labels and secondary luminescent signals
WO2021163701A1 (en) * 2020-02-13 2021-08-19 Escape Therapeutics, Inc. Melanoma therapeutics
CN117337190A (zh) * 2021-01-07 2024-01-02 普渡研究基金会 叶酸受体靶向的缀合物、组合物和向中枢神经系统的递送
TW202317199A (zh) * 2021-06-25 2023-05-01 大陸商同宜醫藥（蘇州）有限公司 配體藥物偶聯物及其應用
CN116059392B (zh) * 2021-09-03 2025-02-28 同宜医药（苏州）有限公司 配体偶联物及其应用
CN118475346A (zh) * 2021-09-08 2024-08-09 同宜医药（苏州）有限公司 药物制剂及其制备方法和用途
CA3235106A1 (en) * 2021-10-19 2023-04-27 Sixiang FAN Conjugate pharmaceutical preparation, preparation method therefor and use thereof______________
CN116196408A (zh) * 2021-12-30 2023-06-02 思格(苏州)生物科技有限公司 一种新型免疫佐剂及其制备方法和应用
TW202404643A (zh) * 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
WO2024099387A1 (zh) * 2022-11-09 2024-05-16 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗癌症
CN120813385A (zh) * 2023-03-23 2025-10-17 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗卵巢癌
WO2024222803A1 (zh) * 2023-04-26 2024-10-31 同宜医药（苏州）有限公司 一种配体-药物偶联体在治疗癌症中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
JP5021152B2 (ja) * 2001-10-22 2012-09-05 ザ スクリプス リサーチ インスティチュート インテグリンターゲッティング化合物
US20050171014A1 (en) * 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
WO2005055980A2 (en) 2003-12-05 2005-06-23 Arrogene, Inc. Polymalic acid-based multifunctional drug delivery system
US20100166654A1 (en) 2004-12-03 2010-07-01 The Uab Research Foundation Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery
JP5475992B2 (ja) 2005-08-19 2014-04-16 エンドサイト，インコーポレイテッド 多剤リガンド結合体
NZ566982A (en) * 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101224306B (zh) * 2008-02-20 2011-04-20 中山大学 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法
WO2010057154A1 (en) 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Releasable conjugates for nucleic acids delivery systems
KR20110112301A (ko) * 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
EP2600900A4 (en) * 2010-08-06 2014-11-19 Univ Illinois SUPRAMOLECULAR MULTIPLEX AGGREGATES FOR THE NONVIRAL OUTPUT OF GENETIC MATERIALS
EP2729179B1 (en) 2011-06-06 2020-09-23 Starpharma Pty Ltd Macromolecules
AU2013226090B2 (en) * 2012-02-27 2018-03-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
CN103372199B (zh) * 2012-04-16 2015-12-16 广州暨南大学医药生物技术研究开发中心 一种预防和治疗神经退行性疾病的新型脑部靶向制剂
JP6290187B2 (ja) * 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
GB201211309D0 (en) 2012-06-26 2012-08-08 Fujifilm Mfg Europe Bv Process for preparing membranes
US20140030282A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
EP3348280A1 (en) 2012-07-12 2018-07-18 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
JP2016501881A (ja) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
US10253099B2 (en) 2012-12-05 2019-04-09 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
RU2016134258A (ru) 2013-10-15 2018-02-28 Сорренто Терапьютикс Инк. Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
CN104784699B (zh) 2014-01-20 2019-05-03 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN104667292B (zh) * 2015-02-02 2017-09-05 北京大学 一种还原响应型药物偶联物纳米粒的制备及其应用
JP6987641B2 (ja) * 2015-05-12 2022-01-05 ブリンクバイオ インコーポレイテッド シリコン系薬物複合体及びその使用方法
CN108135881B (zh) * 2015-08-11 2020-11-13 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
JP2020164335A (ja) * 2019-03-28 2020-10-08 イビデン株式会社 ハニカム構造体

Also Published As

Publication number Publication date
AU2019240611A1 (en) 2019-10-17
KR20180033513A (ko) 2018-04-03
KR102464778B1 (ko) 2022-11-07
CA2987322A1 (en) 2017-02-16
EP3334500A4 (en) 2019-04-03
WO2017025057A1 (en) 2017-02-16
EP3334500B1 (en) 2021-04-07
CA2987322C (en) 2020-02-11
MX381031B (es) 2025-03-12
MX2018001723A (es) 2018-05-17
RU2722449C2 (ru) 2020-06-01
JP2018529632A (ja) 2018-10-11
KR20200071152A (ko) 2020-06-18
US20180200377A1 (en) 2018-07-19
JP6772199B2 (ja) 2020-10-21
JP2021006549A (ja) 2021-01-21
DK3334500T3 (da) 2021-06-21
AU2019240611B2 (en) 2021-09-09
JP7573401B2 (ja) 2024-10-25
ES2877409T3 (es) 2021-11-16
CN108135881A (zh) 2018-06-08
CN112263683A (zh) 2021-01-26
HK1250634A1 (zh) 2019-01-11
ZA201707464B (en) 2021-05-26
EP3334500A1 (en) 2018-06-20
CN111617250B (zh) 2022-07-01
CN111617250A (zh) 2020-09-04
US11571480B2 (en) 2023-02-07
JP2023025151A (ja) 2023-02-21
AU2016305703A1 (en) 2017-11-23
US20240100175A1 (en) 2024-03-28
RU2018104266A (ru) 2019-09-12
KR102301596B1 (ko) 2021-09-14
AU2016305703B2 (en) 2019-07-25
CN108135881B (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
BR122021018243A2 (enExample)
RU2018104266A3 (enExample)
BR112017027930A2 (enExample)
BR112018005507A2 (enExample)
AU2022228198B1 (enExample)
BE2015C047I2 (enExample)
BR0007834B1 (enExample)
BR0009757B1 (enExample)
CN303069822S (enExample)
CN303069496S (enExample)
CN303069435S (enExample)
CN303068955S (enExample)
CN303071301S (enExample)
BR0000126B1 (enExample)
CN303068733S (enExample)
CN303063474S (enExample)
BR8302297Y1 (enExample)
CN303071312S (enExample)
CN303071704S (enExample)
CN303071940S (enExample)
BR0012149B1 (enExample)
BR0010384B1 (enExample)
BR0000695B1 (enExample)
BR0000763F1 (enExample)
BR0003208B1 (enExample)

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20210608